Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
I-MAB ( (IMAB) ) just unveiled an update.
On June 26, 2025, I-Mab announced positive results from a Phase 1b study of givastomig, a bispecific antibody, in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers. The study, presented at the ESMO GI 2025, showed a 71% objective response rate (ORR) across all dose levels, with an 83% ORR at selected doses for ongoing expansion. The treatment demonstrated a favorable safety profile and efficacy in patients with low PD-L1 and/or CLDN18.2 expression. These results enhance I-Mab’s positioning in the oncology market by showcasing the potential of givastomig as a promising first-line treatment for gastric cancers, potentially impacting stakeholders by advancing therapeutic options for significant unmet medical needs.
The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-Mab is a U.S.-based, global biotech company focused on the development of precision immuno-oncology agents for the treatment of cancer. The company’s pipeline is led by givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers by activating T cells through the 4-1BB signaling pathway.
Average Trading Volume: 467,870
Technical Sentiment Signal: Buy
Current Market Cap: $219.5M
See more insights into IMAB stock on TipRanks’ Stock Analysis page.